Atsushi Sanbe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Atsushi Sanbe has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Hideo Nishigori
Department of Pharmacotherapeutics, School of Pharmacy, Iwate Medical University, Iwate 028-3694, Japan
4 shared publicationsJunji Yamauchi
Department of Pharmacology, National Research Institute for Child Health and Development, Tokyo 157-8535, Japan
4 shared publicationsHideki Tsumura
Division of Laboratory Animal Resources, National Institute for Child Health and Development, Tokyo, 157-8535, Japan
3 shared publicationsYu Tezuka
Department of Pharmacotherapeutics, School of Pharmacy, Iwate Medical University, Iwate 028-3694, Japan
3 shared publicationsYui Inomata
Division of Pharmacotherapeutics, Department of Pathophysiology and Pharmacology, School of Pharmacy, Iwate Medical University, Iwate, 028-3694, Japan
3 shared publicationsAkito Tanoue
2 shared publications
Latest Publications
- Open Access
- 16 September 2022
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 631, 48-54
Modification of cardiac disease by transgenically altered histone deacetylase 6
- 16 September 2022
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 631, 48-54
Open AccessModification of cardiac disease by transgenically altered histone deacetylase 6
- 1 February 2018
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 496 (4) , 1141-1147
Bcl-2-associated athanogene 3 (BAG3) is an enhancer of small heat shock protein turnover via activation of autophagy in the heart
- 1 February 2018
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 496 (4) , 1141-1147
Bcl-2-associated athanogene 3 (BAG3) is an enhancer of small heat shock protein turnover via activation of autophagy in the heart
- 1 March 2017
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 485 (1) , 102-106
Analysis of serotonin concentrations in human milk by high-performance liquid chromatography with fluorescence detection
- 1 March 2017
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 485 (1) , 102-106
Analysis of serotonin concentrations in human milk by high-performance liquid chromatography with fluorescence detection
- 1 November 2015
- Published by Elsevier in European Journal of Pharmacology
- Vol. 766, 56-62
Inhibitory effect of fluvoxamine on β-casein expression via a serotonin-independent mechanism in human mammary epithelial cells
- 1 November 2015
- Published by Elsevier in European Journal of Pharmacology
- Vol. 766, 56-62
Inhibitory effect of fluvoxamine on β-casein expression via a serotonin-independent mechanism in human mammary epithelial cells
- 1 May 2015
- Published by Elsevier in Life Sciences
- Vol. 128, 94-100
Upregulation of inorganic pyrophosphatase 1 as a JNK phosphatase in hypothyroid embryonic chick cerebellum
- 1 May 2015
- Published by Elsevier in Life Sciences
- Vol. 128, 94-100
Upregulation of inorganic pyrophosphatase 1 as a JNK phosphatase in hypothyroid embryonic chick cerebellum
- Open Access
- 23 April 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (4) , e61649
Regulation of Neurite Growth by Inorganic Pyrophosphatase 1 via JNK Dephosphorylation
Neural cell differentiation during development is controlled by multiple signaling pathways, in which protein phosphorylation and dephosphorylation play an important role. In this study, we examined the role of pyrophosphatase1 (PPA1) in neuronal differentiation using the loss and gain of function analysis. Neuronal differentiation induced by external factors was studied using a mouse neuroblastoma cell line (N1E115). The neuronal like differentiation in N1E115 cells was determined by morphological analysis based on neurite growth length. In order to analyze the loss of the PPA1 function in N1E115, si-RNA specifically targeting PPA1 was generated. To study the effect of PPA1 overexpression, an adenoviral gene vector containing the PPA1 gene was utilized to infect N1E115 cells. To address the need for pyrophosphatase activity in PPA1, D117A PPA1, which has inactive pyrophosphatase, was overexpressed in N1E115 cells. We used valproic acid (VPA) as a neuronal differentiator to examine the effect of PPA1 in actively differentiated N1E115 cells. Si-PPA1 treatment reduced the PPA1 protein level and led to enhanced neurite growth in N1E115 cells. In contrast, PPA1 overexpression suppressed neurite growth in N1E115 cells treated with VPA, whereas this effect was abolished in D117A PPA1. PPA1 knockdown enhanced the JNK phosphorylation level, and PPA1 overexpression suppressed it in N1E115 cells. It seems that recombinant PPA1 can dephosphorylate JNK while no alteration of JNK phosphorylation level was seen after treatment with recombinant PPA1 D117A. Enhanced neurite growth by PPA1 knockdown was also observed in rat cortical neurons. Thus, PPA1 may play a role in neuronal differentiation via JNK dephosphorylation.
- 23 April 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (4) , e61649
Open AccessRegulation of Neurite Growth by Inorganic Pyrophosphatase 1 via JNK Dephosphorylation
Neural cell differentiation during development is controlled by multiple signaling pathways, in which protein phosphorylation and dephosphorylation play an important role. In this study, we examined the role of pyrophosphatase1 (PPA1) in neuronal differentiation using the loss and gain of function analysis. Neuronal differentiation induced by external factors was studied using a mouse neuroblastoma cell line (N1E115). The neuronal like differentiation in N1E115 cells was determined by morphological analysis based on neurite growth length. In order to analyze the loss of the PPA1 function in N1E115, si-RNA specifically targeting PPA1 was generated. To study the effect of PPA1 overexpression, an adenoviral gene vector containing the PPA1 gene was utilized to infect N1E115 cells. To address the need for pyrophosphatase activity in PPA1, D117A PPA1, which has inactive pyrophosphatase, was overexpressed in N1E115 cells. We used valproic acid (VPA) as a neuronal differentiator to examine the effect of PPA1 in actively differentiated N1E115 cells. Si-PPA1 treatment reduced the PPA1 protein level and led to enhanced neurite growth in N1E115 cells. In contrast, PPA1 overexpression suppressed neurite growth in N1E115 cells treated with VPA, whereas this effect was abolished in D117A PPA1. PPA1 knockdown enhanced the JNK phosphorylation level, and PPA1 overexpression suppressed it in N1E115 cells. It seems that recombinant PPA1 can dephosphorylate JNK while no alteration of JNK phosphorylation level was seen after treatment with recombinant PPA1 D117A. Enhanced neurite growth by PPA1 knockdown was also observed in rat cortical neurons. Thus, PPA1 may play a role in neuronal differentiation via JNK dephosphorylation.
- Open Access
- 1 March 2013
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 288 (13) , 8910-8921
Phenotype of Cardiomyopathy in Cardiac-specific Heat Shock Protein B8 K141N Transgenic Mouse
- 1 March 2013
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 288 (13) , 8910-8921
Open AccessPhenotype of Cardiomyopathy in Cardiac-specific Heat Shock Protein B8 K141N Transgenic Mouse
- Open Access
- 1 January 2013
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 36 (1) , 18-22
Dilated Cardiomyopathy: A Disease of the Myocardium
Cardiomyopathies are defined as cardiac diseases of the myocardium with associated cardiac dysfunction. They are cardiac diseases in which heart muscle disease and/or measurable deterioration of cardiac muscle function occurs due to various causes, such as genetic and sporadic mutations of muscle proteins, as well as external factors such as hypertension, ischemia, and inflammation. In 1995, the WHO/International Society and Federation of Cardiology (ISFC) classified primary cardiomyopathy caused by intrinsic factors into five groups according to the dominant pathophysiology: dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), restricted cardiomyopathy (RCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), and unclassified cardiomyopathy. Among these cardiomyopathies, DCM is the most prevalent and the most common reason for cardiac transplantation in adults and children. Many recent findings indicate that genetic and sporadic mutations of a number of muscle proteins, such as myofibrillar, structural, and Ca2+ regulating proteins, can cause DCM. In such cases, certain mutations often induce DCM with cardiac arrhythmia that is recognized as a potential trigger of sudden cardiac death. Thus, effective prognostic determination and appropriate cardiac care depend on accurate molecular and genetic diagnoses.
- 1 January 2013
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 36 (1) , 18-22
Open AccessDilated Cardiomyopathy: A Disease of the Myocardium
Cardiomyopathies are defined as cardiac diseases of the myocardium with associated cardiac dysfunction. They are cardiac diseases in which heart muscle disease and/or measurable deterioration of cardiac muscle function occurs due to various causes, such as genetic and sporadic mutations of muscle proteins, as well as external factors such as hypertension, ischemia, and inflammation. In 1995, the WHO/International Society and Federation of Cardiology (ISFC) classified primary cardiomyopathy caused by intrinsic factors into five groups according to the dominant pathophysiology: dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), restricted cardiomyopathy (RCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), and unclassified cardiomyopathy. Among these cardiomyopathies, DCM is the most prevalent and the most common reason for cardiac transplantation in adults and children. Many recent findings indicate that genetic and sporadic mutations of a number of muscle proteins, such as myofibrillar, structural, and Ca2+ regulating proteins, can cause DCM. In such cases, certain mutations often induce DCM with cardiac arrhythmia that is recognized as a potential trigger of sudden cardiac death. Thus, effective prognostic determination and appropriate cardiac care depend on accurate molecular and genetic diagnoses.
- Open Access
- 1 January 2012
- Published by Japanese Pharmacological Society in Folia Pharmacologica Japonica
- Vol. 139 (6) , 256-259
Molecular mechanisms of small heat shock protein^|^ndash;related disease and its therapeutic strategies
- 1 January 2012
- Published by Japanese Pharmacological Society in Folia Pharmacologica Japonica
- Vol. 139 (6) , 256-259
Open AccessMolecular mechanisms of small heat shock protein^|^ndash;related disease and its therapeutic strategies
- Open Access
- 25 April 2011
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (4) , e18922
Cardioprotective Effect of Nicorandil, a Mitochondrial ATP-Sensitive Potassium Channel Opener, Prolongs Survival in HSPB5 R120G Transgenic Mice
Transgenic (TG) mice with overexpression of an arg120gly (R120G) missense mutation in HSPB5 display desmin-related cardiomyopathy, which is characterized by formation of aggresomes. It is also known that progressive mitochondrial abnormalities and apoptotic cell death occur in the hearts of R120G TG mice. The role of mitochondrial dysfunction and apoptosis in disease progression, however, remains uncertain. Mitochondrial abnormalities and apoptotic cell death induced by overexpression of HSPB5 R120G were analyzed in neonatal rat cardiomyocytes. Overexpression of mutant HSPB5 led to development of aggresomes with a concomitant reduction in cell viability in the myocytes. Overexpression of mutant HSPB5 induced a reduction in the cytochrome c level in the mitochondrial fraction and a corresponding increase in the cytoplasmic fraction in the myocytes. Down-regulation of BCL2 and up-regulation of BAX were detected in the myocytes expressing the mutant HSPB5. Concomitant with mitochondrial abnormality, the activation of caspase-3 and increased apoptotic cell death was observed. Cell viability was dose-dependently recovered in myocytes overexpressing HSPB5 R120G by treatment with nicorandil a mitochondrial ATP-sensitive potassium channel opener. Nicorandil treatment also inhibited the increase in BAX, the decrease in BCL2, activation of caspase-3 and apoptotic cell death by mutant HSPB5. To confirm the results of the in-vitro study, we analyzed the effect of nicorandil in HSPB5 R120G TG mice. Nicorandil treatment appeared to reduce mitochondrial impairment and apoptotic cell death and prolonged survival in HSPB5 R120G TG mice. Nicorandil may prolong survival in HSPB5 R120G TG mice by protecting against mitochondrial impairments.
- 25 April 2011
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (4) , e18922
Open AccessCardioprotective Effect of Nicorandil, a Mitochondrial ATP-Sensitive Potassium Channel Opener, Prolongs Survival in HSPB5 R120G Transgenic Mice
Transgenic (TG) mice with overexpression of an arg120gly (R120G) missense mutation in HSPB5 display desmin-related cardiomyopathy, which is characterized by formation of aggresomes. It is also known that progressive mitochondrial abnormalities and apoptotic cell death occur in the hearts of R120G TG mice. The role of mitochondrial dysfunction and apoptosis in disease progression, however, remains uncertain. Mitochondrial abnormalities and apoptotic cell death induced by overexpression of HSPB5 R120G were analyzed in neonatal rat cardiomyocytes. Overexpression of mutant HSPB5 led to development of aggresomes with a concomitant reduction in cell viability in the myocytes. Overexpression of mutant HSPB5 induced a reduction in the cytochrome c level in the mitochondrial fraction and a corresponding increase in the cytoplasmic fraction in the myocytes. Down-regulation of BCL2 and up-regulation of BAX were detected in the myocytes expressing the mutant HSPB5. Concomitant with mitochondrial abnormality, the activation of caspase-3 and increased apoptotic cell death was observed. Cell viability was dose-dependently recovered in myocytes overexpressing HSPB5 R120G by treatment with nicorandil a mitochondrial ATP-sensitive potassium channel opener. Nicorandil treatment also inhibited the increase in BAX, the decrease in BCL2, activation of caspase-3 and apoptotic cell death by mutant HSPB5. To confirm the results of the in-vitro study, we analyzed the effect of nicorandil in HSPB5 R120G TG mice. Nicorandil treatment appeared to reduce mitochondrial impairment and apoptotic cell death and prolonged survival in HSPB5 R120G TG mice. Nicorandil may prolong survival in HSPB5 R120G TG mice by protecting against mitochondrial impairments.